Avanos Medical Management
Management Kriterienprüfungen 2/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Joe Woody
Geschäftsführender
US$7.2m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 14.1% |
| Amtszeit als Geschäftsführer | 7yrs |
| Eigentum des Geschäftsführers | 0.6% |
| Durchschnittliche Amtszeit des Managements | 3.8yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 9.7yrs |
Jüngste Management Updates
Recent updates
Lacklustre Performance Is Driving Avanos Medical, Inc.'s (NYSE:AVNS) Low P/S
Apr 17
Is Avanos Medical (NYSE:AVNS) A Risky Investment?
Jan 05Some Avanos Medical, Inc. (NYSE:AVNS) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 14When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
Aug 13Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy
Jul 16We Think Avanos Medical (NYSE:AVNS) Can Manage Its Debt With Ease
Jun 05Avanos Medical, Inc. (NYSE:AVNS) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing
May 18Avanos Medical (NYSE:AVNS) Is Looking To Continue Growing Its Returns On Capital
May 07Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
Mar 02Avanos Medical Q4 2022 Earnings Preview
Feb 20Avanos Medical, Inc. (NYSE:AVNS) Shares Could Be 30% Below Their Intrinsic Value Estimate
Feb 10Why Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching
Jan 13Avanos Medical reports Q3 mixed earnings; reaffirms FY22 guidance
Nov 02Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate
Sep 12Avanos Medical Q2 2022 Earnings Preview
Aug 08When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
May 28Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
May 03Is There An Opportunity With Avanos Medical, Inc.'s (NYSE:AVNS) 41% Undervaluation?
Feb 10Should You Think About Buying Avanos Medical, Inc. (NYSE:AVNS) Now?
Dec 21An Intrinsic Calculation For Avanos Medical, Inc. (NYSE:AVNS) Suggests It's 33% Undervalued
Nov 04Avanos Medical (NYSE:AVNS) Takes On Some Risk With Its Use Of Debt
Sep 10The Strong Earnings Posted By Avanos Medical (NYSE:AVNS) Are A Good Indication Of The Strength Of The Business
Aug 10Is There Now An Opportunity In Avanos Medical, Inc. (NYSE:AVNS)?
Jun 30We Think Avanos Medical (NYSE:AVNS) Is Taking Some Risk With Its Debt
Jun 09Avanos Medical Q1 2021 Earnings Preview
May 06Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$7m | US$1m | -US$10m |
| Sep 30 2023 | n/a | n/a | -US$11m |
| Jun 30 2023 | n/a | n/a | US$9m |
| Mar 31 2023 | n/a | n/a | US$18m |
| Dec 31 2022 | US$7m | US$1m | US$22m |
| Sep 30 2022 | n/a | n/a | US$23m |
| Jun 30 2022 | n/a | n/a | -US$23m |
| Mar 31 2022 | n/a | n/a | US$10m |
| Dec 31 2021 | US$5m | US$960k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$52m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$8m | US$939k | -US$29m |
| Sep 30 2020 | n/a | n/a | US$14m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$5m | US$932k | -US$46m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$6m | US$905k | -US$8m |
| Sep 30 2018 | n/a | n/a | -US$1m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$7m | US$443k | -US$32m |
Vergütung im Vergleich zum Markt: JoeDie Gesamtvergütung ($USD7.21M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD3.39M).
Entschädigung vs. Einkommen: JoeDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Joe Woody (58 yo)
7yrs
Amtszeit
US$7,214,563
Vergütung
Mr. Joseph F. Woody, also known as Joe, has been Chief Executive Officer and Director of Avanos Medical, Inc. (formerly known as Halyard Health, Inc.) since June 26, 2017. He joined the Avanos Medical, Inc...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$7.21m | 0.59% $ 4.9m | |
| Senior VP | 4.4yrs | US$2.99m | 0.13% $ 1.1m | |
| Senior VP | 2.9yrs | US$1.90m | 0.041% $ 339.5k | |
| Senior VP & Chief Commercial Officer | 5.1yrs | US$2.15m | 0.20% $ 1.7m | |
| Principal Accounting Officer & Controller | 2.2yrs | keine Daten | 0.0091% $ 75.7k | |
| VP of FP&A and Investor Relations and Treasurer | no data | keine Daten | keine Daten | |
| Senior VP and Chief Ethics & Compliance Officer | 3.8yrs | keine Daten | keine Daten | |
| Vice President of Strategy & Corporate Development | no data | keine Daten | keine Daten | |
| Vice President of Human Resources | no data | keine Daten | keine Daten | |
| Senior Vice President of Global R&D | no data | keine Daten | keine Daten | |
| Senior Vice President of Integrated Supply Chain | less than a year | keine Daten | keine Daten |
3.8yrs
Durchschnittliche Betriebszugehörigkeit
57yo
Durchschnittliches Alter
Erfahrenes Management: AVNSDas Führungsteam des Unternehmens gilt als erfahren (3.8 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$7.21m | 0.59% $ 4.9m | |
| Independent Director | 9.7yrs | US$292.54k | 0.13% $ 1.1m | |
| Independent Chairman | 9.7yrs | US$390.00k | 0.14% $ 1.2m | |
| Independent Director | 1.3yrs | US$245.15k | 0.032% $ 267.0k | |
| Independent Director | 9.7yrs | US$289.38k | 0.12% $ 968.2k |
9.7yrs
Durchschnittliche Betriebszugehörigkeit
66yo
Durchschnittliches Alter
Erfahrener Vorstand: AVNSDie Vorstandsmitglieder gelten als erfahren (9.7 Jahre durchschnittliche Amtszeit).